as the presentation is indistinguishable from other respiratory tract infections, and epidemics often overlap. The microbiologic confirmation of RSV infection is based on detecting the virus in a ...

The following is a summary of “EDP-938 has a high barrier to resistance in healthy adults experimentally infected with ...

Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...

The highly contagious respiratory syncytial virus (RSV) typically causes mild illness, but it can lead to severe respiratory complications, particularly for at-risk individuals. Drawing on local ...

As the colder months set in, there are concerns that a 'tripledemic' could be on the horizon, with a potential surge in cases ...

Respiratory syncytial virus (RSV) is caused by a virus that spreads through contact with an infected person's respiratory ...

Oct. 18, 2024 – Older people who aren’t sure about whether to get the vaccine for respiratory syncytial virus (RSV) now have a new set of data to help them make up their minds. A large study ...

2024 — This multi-state study is a real world data analyses of the effectiveness of the RSV -- short for respiratory syncytial virus -- vaccine. VISION ... Nov. 7, 2024 — Increased ...

What if infections of respiratory ... What if a novel virus destined to be called SARS-CoV-3 emerges from a horseshoe bat in a rural village somewhere, gains a few key mutations and comes ...

Recruitment is underway for a clinical trial testing a vaccine candidate produced with The University of Queensland's molecular clamp technology against life-threatening respiratory viruses.

On Tuesday, the FDA approved Pfizer Inc’s (NYSE:PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract ...

Disease surveillance and genomic analyses in northeast China identifies the emerging tick-borne Yezo virus in 2% of 988 ...